28399-82-8

Basic information

• Product Name: 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester
• Synonyms: 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester;ethyl 2-(1-methylpiperidin-4-ylidene)acetate
• CAS NO: 28399-82-8
• Molecular Formula: C10H17NO2
• Molecular Weight: 183.24748
• Product Categories: Heterocycles, Miscellaneous Reagents
• Mol File: 28399-82-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 260.2°Cat760mmHg
• Flash Point: 97.6°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 0.0124mmHg at 25°C
• Refractive Index: 1.534
• CAS DataBase Reference: 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester(28399-82-8)
• EPA Substance Registry System: 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester(28399-82-8)

Safety Data

• Hazardous Substances Data: 28399-82-8(Hazardous Substances Data)

Usage

Description

2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a methyl group, a piperidine ring, and an ester functional group.

Uses

Used in Pharmaceutical Industry:
2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester is used as a synthetic intermediate for the production of oxadiazaspirodecanones and other ketone functional related compounds. These compounds are known to act as M1 muscarinic agonists, which have potential applications in the treatment of various neurological and cognitive disorders, such as Alzheimer's disease and schizophrenia.
In the synthesis of these compounds, 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester plays a crucial role in providing the necessary structural elements and functional groups that enable the formation of the desired pharmacologically active molecules. Its versatility in chemical reactions and compatibility with various synthetic routes make it a valuable component in the development of novel therapeutic agents.

InChI:InChI=1/C10H17NO2/c1-3-13-10(12)8-9-4-6-11(2)7-5-9/h8H,3-7H2,1-2H3

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 931-20-4 1-methylpiperidin-2-one 

Downstream Products

• 123318-91-2 2-ethyl-8-methyl-1-oxa-8-azaspiro<4.5>decan-3-one 
• 132041-83-9 (-)-2-ethyl-8-methyl-1-oxa-8-azaspiro<4.5>decan-3-one 
• 132041-83-9 (+)-2-ethyl-8-methyl-1-oxa-8-azaspiro<4.5>decan-3-one 
• 132041-81-7 (S)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro<4,5>decane 
• 67686-05-9 (1-methyl-[4]piperidyl)-acetic acid ethyl ester 

Relevant articles and documents

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.